This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Costagliola, S. Articles by Usadel, K.-H. Search for Related Content PubMed PubMed Citation Articles by Costagliola, S. Articles by Usadel, K.-H.

Second Generation Assay for Thyrotropin Receptor Antibodies Has Superior Diagnostic Sensitivity for Graves’ Disease

I.R.I.B.H.N., ULB (S.C., J.E.D., G.V.), and Euroscreen (S.C.), Brussels, Belgium; and Research Laboratories, B.R.A.H.M.S Diagnostica GmbH (N.G.M., J.S., W.W., J.M.H., A.B.), D-12099 Berlin; the Division of Endocrinology, Department of Medicine, University of Essen (R.H., S.P., B.Q., K.M.), D-45122 Essen; and the Center of Internal Medicine, University of Frankfurt (K.B., D.F., P.-M.S.-D., K.-H.U.), D-60950 Frankfurt, Germany

Address all correspondence and requests for reprints to: Dr. Nils G. Morgenthaler, Research Laboratories, B.R.A.H.M.S Diagnostica GmbH, Komturstrasse 19–20, D-12099 Berlin, Germany. E-mail: morgenthaler{at}brahms.de or Prof. Dr. Klaus-Henning Usadel, Zentrum

Detection of autoantibodies to the TSH receptor (TSH-R) in Graves’ disease has found widespread use in clinical routine and is performed mostly by commercial RRAs measuring TSH binding inhibitory activity. We report in this study on a second generation TSH binding inhibitory assay using the human recombinant TSH-R with two major improvements: 1) superior diagnostic sensitivity for Graves’ disease, and 2) for the first time, nonradioactive and radioactive coated tube (CT) technology. Full-length human recombinant TSH-R was expressed in the K562 leukemia cell line and grown in suspension at a high density. A murine monoclonal antibody was selected for binding to the native TSH-R without interfering with autoantibodies or TSH and was coated to polystyrene tubes. After detergent extraction, TSH-R was affinity immobilized on antibody-coated tubes. The binding of TSH to the TSH-R could be demonstrated by the addition of ¹²⁵I- or acridinium ester-labeled bovine TSH, and this binding could be inhibited by sera from patients with Graves’ disease up to 95%. Subsequently, these novel assays, a CT RRA and a CT luminescence receptor assay, were compared to the conventional RRA based on porcine antigen in a blinded clinical multicenter trial. Sera from 328 patients with Graves’ disease (86 untreated, 116 treated, and 126 in remission) and 520 controls (comprised of healthy blood donors and patients with autoimmune diseases or goiter) were tested in all 3 assays. Receiver-operating characteristic plot analysis resulted in a specificity of 99.6% with a sensitivity of 98.8% for both CT assays, compared to 99.6% specificity and 80.2% sensitivity for the conventional RRA (P < 0.001). In all 3 groups of patients with Graves’ disease, the 2 CT assays were significantly more sensitive for the disease than the conventional assay, without loss of specificity in the control groups. This increase in sensitivity and the nonradioactive or radioactive CT format constitute a significant improvement over the currently available assays.

This article has been cited by other articles:

				S. Stavrakis, X. Yu, E. Patterson, S. Huang, S. R. Hamlett, L. Chalmers, R. Pappy, M. W. Cunningham, S. A. Morshed, T. F. Davies, et al. Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1309 - 1316. [Abstract] [Full Text] [PDF]

				A K Eckstein, C Losch, D Glowacka, M Schott, K Mann, J Esser, and N G Morgenthaler Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy Br J Ophthalmol, August 1, 2009; 93(8): 1052 - 1056. [Abstract] [Full Text] [PDF]

				C. Massart, R. Sapin, J. Gibassier, A. Agin, and M. d'Herbomez Intermethod Variability in TSH-Receptor Antibody Measurement: Implication for the Diagnosis of Graves Disease and for the Follow-Up of Graves Ophthalmopathy Clin. Chem., January 1, 2009; 55(1): 183 - 186. [Abstract] [Full Text] [PDF]

				N. G. Morgenthaler, S. C. Ho, and W. B. Minich Stimulating and Blocking Thyroid-Stimulating Hormone (TSH) Receptor Autoantibodies from Patients with Graves' Disease and Autoimmune Hypothyroidism Have Very Similar Concentration, TSH Receptor Affinity, and Binding Sites J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1058 - 1065. [Abstract] [Full Text] [PDF]

				A. K. Eckstein, M. Plicht, H. Lax, M. Neuhauser, K. Mann, S. Lederbogen, C. Heckmann, J. Esser, and N. G. Morgenthaler Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves' Ophthalmopathy and Help to Predict Severity and Outcome of the Disease J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3464 - 3470. [Abstract] [Full Text] [PDF]

				H. Inaba, W. Martin, A. S. De Groot, S. Qin, and L. J. De Groot Thyrotropin Receptor Epitopes and Their Relation to Histocompatibility Leukocyte Antigen-DR Molecules in Graves' Disease J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2286 - 2294. [Abstract] [Full Text] [PDF]

				M. Salvi, G. Vannucchi, I. Campi, S. Rossi, P. Bonara, F. Sbrozzi, C. Guastella, S. Avignone, G. Pirola, R. Ratiglia, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol., April 1, 2006; 154(4): 511 - 517. [Abstract] [Full Text] [PDF]

				E. Jensen, P. H. Petersen, O. Blaabjerg, P. S. Hansen, and L. Hegedus Improved Sensitivity of a Thyrotropin Receptor Antibody Assay Clin. Chem., November 1, 2005; 51(11): 2186 - 2187. [Full Text] [PDF]

				G. Mazziotti, F. Sorvillo, M. Piscopo, F. Morisco, M. Cioffi, G. Stornaiuolo, G. B. Gaeta, A. M. Molinari, J. H. Lazarus, G. Amato, et al. Innate and Acquired Immune System in Patients Developing Interferon-{alpha}-Related Autoimmune Thyroiditis: A Prospective Study J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4138 - 4144. [Abstract] [Full Text] [PDF]

				S. Costagliola, M. Bonomi, N. G. Morgenthaler, J. Van Durme, V. Panneels, S. Refetoff, and G. Vassart Delineation of the Discontinuous-Conformational Epitope of a Monoclonal Antibody Displaying Full in Vitro and in Vivo Thyrotropin Activity Mol. Endocrinol., December 1, 2004; 18(12): 3020 - 3034. [Abstract] [Full Text] [PDF]

				D Villalta, E Orunesu, R Tozzoli, P Montagna, G Pesce, N Bizzaro, and M Bagnasco Analytical and diagnostic accuracy of "second generation" assays for thyrotrophin receptor antibodies with radioactive and chemiluminescent tracers J. Clin. Pathol., April 1, 2004; 57(4): 378 - 382. [Abstract] [Full Text] [PDF]

				P. Rodien, N. Jordan, A. Lefevre, J. Royer, C. Vasseur, F. Savagner, A. Bourdelot, and V. Rohmer Abnormal stimulation of the thyrotrophin receptor during gestation Hum. Reprod. Update, March 1, 2004; 10(2): 95 - 105. [Abstract] [Full Text] [PDF]

				W. B. Minich, C. Lenzner, A. Bergmann, and N. G. Morgenthaler A Coated Tube Assay for the Detection of Blocking Thyrotropin Receptor Autoantibodies J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 352 - 356. [Abstract] [Full Text] [PDF]

				C. M. Preissner, P. J. Wolhuter, J. W. Sistrunk, H. A. Homburger, and J. C. Morris III Comparison of Thyrotropin-Receptor Antibodies Measured by Four Commercially Available Methods with a Bioassay That Uses Fisher Rat Thyroid Cells Clin. Chem., August 1, 2003; 49(8): 1402 - 1404. [Full Text] [PDF]

				L. Parker, F. Relimpio, and A. Toft Subclinical Hyperthyroidism N. Engl. J. Med., January 3, 2002; 346(1): 67 - 68. [Full Text] [PDF]

				A. D. Toft Subclinical Hyperthyroidism N. Engl. J. Med., August 16, 2001; 345(7): 512 - 516. [Full Text] [PDF]

				G. D. Chazenbalk, S. M. McLachlan, P. Pichurin, X.-M. Yan, and B. Rapoport A Prion-Like Shift between Two Conformational Forms of a Recombinant Thyrotropin Receptor A-Subunit Module: Purification and Stabilization Using Chemical Chaperones of the Form Reactive with Graves' Autoantibodies J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1287 - 1293. [Abstract] [Full Text]

				J. Seissler, S. Wagner, M. Schott, M. Lettmann, J. Feldkamp, W. A. Scherbaum, and N. G. Morgenthaler Low Frequency of Autoantibodies to the Human Na+/I- Symporter in Patients with Autoimmune Thyroid Disease J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4630 - 4634. [Abstract] [Full Text]

				A. P. Weetman Graves' Disease N. Engl. J. Med., October 26, 2000; 343(17): 1236 - 1248. [Full Text] [PDF]

				J. Sanders, Y. Oda, S. Roberts, A. Kiddie, T. Richards, J. Bolton, V. McGrath, S. Walters, D. Jaskolski, J. Furmaniak, et al. The Interaction of TSH Receptor Autoantibodies with 125I-Labelled TSH Receptor J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3797 - 3802. [Abstract] [Full Text] [PDF]